CRISPR THERAPEUTICS AG Lessee, Operating Lease, Liability, to be Paid, Year One
CRISPR THERAPEUTICS AG (CRSP) had Lessee, Operating Lease, Liability, to be Paid, Year One of $29.68 million as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-02-12
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $29.68M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $29.42M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $28.70M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $29.27M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $29.68M 10-K · filed 2026-02-12 |
| 2024-12-31 | $29.42M 10-K · filed 2025-02-11 |
| 2023-12-31 | $28.70M 10-K · filed 2024-02-21 |
| 2022-12-31 | $29.27M 10-K · filed 2023-02-21 |
| 2021-12-31 | $18.26M 10-K · filed 2022-02-15 |
| 2020-12-31 | $17.02M 10-K · filed 2021-02-16 |
| 2019-12-31 | $13.96M 10-K · filed 2020-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |